Bingham Osborn & Scarborough’s Idexx Laboratories IDXX Stock Holding History

Bingham Osborn & Scarborough’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-889	Closed	-$553K	–	65
2021 Q3	$553K	Buy	889 +13	+1%	+$8.73K	0.04%	82
2021 Q2	$553K	Sell	876 -9	-1%	-$4.97K	0.04%	78
2021 Q1	$433K	Buy	885 +32	+4%	+$16K	0.03%	90
2020 Q4	$426K	Sell	853 -4	-0.5%	-$1.79K	0.03%	78
2020 Q3	$337K	Buy	857 +3	+0.4%	+$1.11K	0.03%	122
2020 Q2	$282K	Buy	854 +4	+0.5%	+$1.16K	0.02%	128
2020 Q1	$206K	Buy	850 +13	+2%	+$3.39K	0.02%	139
2019 Q4	$219K	Sell	837 -17	-2%	-$4.48K	0.02%	154
2019 Q3	$232K	Buy	854 +15	+2%	+$4.17K	0.02%	137
2019 Q2	$231K	Buy	+839	New	+$207K	0.02%	132

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bingham Osborn & Scarborough's IDXX Position: Q4 2021 in Review

Bingham Osborn & Scarborough sold out of Idexx Laboratories (IDXX) in Q4 2021, closing a stake of 889 shares — an estimated $553K sold.

Bingham Osborn & Scarborough first reported a position in IDXX in Q2 2019 and held it in 10 quarters. The position peaked at $553K in Q3 2021. 1,107 funds tracked by Wall St. Rank hold IDXX as of Q4 2021.

Bingham Osborn & Scarborough reported no remaining Idexx Laboratories position as of Q4 2021 after selling out during the quarter.
Bingham Osborn & Scarborough sold 889 Idexx Laboratories shares in Q4 2021, an estimated $553K.
Bingham Osborn & Scarborough first reported a position in Idexx Laboratories in Q2 2019 and held it in 10 quarters.
Bingham Osborn & Scarborough's Idexx Laboratories position peaked at $553K in Q3 2021.
1,107 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2021.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.